title: [Tiagabine--own experience in the refractory epilepsy treatment].
abstract: Tiagabine belongs to a new generation of antiepileptic drugs with a unique mechanism of action. It is well-absorbable from the gastrointestinal tract, has a linear pharmacokinetics, does not affect cognitive function and it interacts poorly with other antiepileptic drugs. Tiagabine is recommended for adults and children past 12 years of age with epilepsy, suffering from partial seizures, with and without secondary generalization. Following the period of a great enthusiasm as to the use of tiagabine, it was put aside, though unfairly, according to the author's own studies as well as the reports in current literature, it still has its place in the treatment of drug-resistant epilepsy.
authors.affiliation: Wydział Nauk o Zdrowiu WSEiP, Kielce. barbarablaszczyk@op.pl
authors.forename: Barbara
authors.initials: B
authors.lastname: Błaszczyk
mesh_terms: D000328:Adult; D000927:Anticonvulsants / Q000627:therapeutic use*; D002648:Child; D002986:Clinical Trials as Topic; D003071:Cognition / Q000187:drug effects; D011307:Drug Prescriptions; D004827:Epilepsy / Q000188:drug therapy*; D006801:Humans; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D009557:Nipecotic Acids / Q000627:therapeutic use*; D000078308:Tiagabine; D016896:Treatment Outcome
chemical_list: D000927:Anticonvulsants; D018696:Neuroprotective Agents; D009557:Nipecotic Acids; D000078308:Tiagabine